fda warning letters compounded semaglutide 2025 september The U.S. Food and Drug Administration (FDA) has issued a to Novo Nordisk over its alleged failure to report adverse side effects, including death, in patients who took its GLP-1 medications FDA Drug Recalls and Warnings:

He further added, We wanted to know why these people have long-term symptoms

In China, the patent expires slightly earlier, in 2026

"The possibility of offering new hope to individuals struggling with addiction is what makes this work so meaningful." Source: Journal reference: Quddos, F., et al

10.1007/s11104-017-3207-z Plant Soil 87 ZhangY.LiuJ.ZhouY.GongT.WangJ.GeY

9 The semaglutide group exhibited significant improvements in symptoms and physical limitations, assessed using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), with the change in KCCQ-CSS being the primary trial endpoint